The Society for Women’s Health Research (SWHR®), in collaboration with the Endocrine Society, hosted a congressional briefing on “Maximizing the Benefits of Biomedical Research: A Tale of Mice and Men, Why We Need to Balance the Study of Males and Females.”
Washington, D.C.—The Society for Women’s Health Research (SWHR®) and the Endocrine Society and are co-sponsoring a Congressional briefing on July 10 to examine the need to include more female subjects in preclinical and clinical biomedical research – a move that could revolutionize medical research and scientific discovery.
The Society for Women’s Health Research (SWHR ®) supports the National Institute of Health’s (NIH) move to include sex as a biological variable in future research. Since 1990, SWHR has been working to increase equality in healthcare research, knowing that there are biological sex differences between women and men, and that these differences matter.
The Society for Women’s Health Research (SWHR®) held its second interdisciplinary roundtable on understanding sex and gender differences in Alzheimer’s disease May 28-29, 2015 at the Hyatt Regency Crystal City in Arlington, Va.
The Food and Drug Administration (FDA) Advisory Committee has made history for women by recommending approval of Sprout Pharmaceuticals’ twice-rejected female libido drug Flibanserin.